AbCellera Biologics Inc.
ABCL | NASDAQ
$12.66
+$0.03 (+0.24%)
At close: Sep 21, 2026, 4:00 PM ET
$12.71
+$0.05 (+0.38%)
Pre-market:
Sep 22, 2026, 8:10 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -6.98 | -5.33 | -11.20 | 18.09 | 25.54 | 89.42 |
PEG Ratio | 0.64 | -0.68 | 0.06 | n/a | 1.04 | -0.02 |
PS Ratio | 13.60 | 29.91 | 43.42 | 5.95 | 10.51 | 45.41 |
PB Ratio | 1.06 | 0.82 | 1.43 | 2.34 | 3.84 | 12.75 |
P/FCF Ratio | -5.87 | -4.61 | -13.60 | 14.11 | 21.19 | 1.32K |
P/OCF Ratio | -7.78 | -7.94 | -37.63 | 10.41 | 16.12 | 466.65 |
OCF/S Ratio | -174.76 | -376.50 | -115.39 | 57.14 | 65.19 | 9.73 |
Debt / Equity Ratio | 0.15 | 0.06 | 0.07 | 0.07 | 0.04 | 0.01 |
Quick Ratio | 11.23 | 9.81 | 7.32 | 8.65 | 7.69 | 7.85 |
Current Ratio | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 |
Asset Turnover | 0.06 | 0.02 | 0.03 | 0.32 | 0.28 | 0.23 |
Interest Coverage | n/a | n/a | n/a | 53.53 | 39.12 | 23.96 |
Return on Equity | -15.14% | -15.42% | -12.70% | 12.85% | 14.96% | 14.32% |
Return on Assets | -10.79% | -11.97% | -9.84% | 10.29% | 11.64% | 11.83% |
Return on Invested Capital | -13.78% | -19.85% | -14.51% | 10.05% | 11.91% | 13.02% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 61.64% | 100% | 100% | 86.31% | 87.87% | 88.36% |
Net Profit Margin | -194.88% | -564.83% | -385% | 32.66% | 40.90% | 51% |
Pretax Profit Margin | -236.39% | -695.02% | -457.67% | 49.26% | 58.41% | 67.69% |
Operating Profit Margin | -288.98% | -1.09K% | -623.82% | 44.60% | 54.48% | 66.92% |
FCF Margin | -231.69% | -648.40% | -319.22% | 42.17% | 49.61% | 3.44% |
EBITDA Margin | -198.03% | -708.04% | -505.35% | 53.60% | 63.74% | 72.75% |
Add to Watchlist
Select watchlists to add or remove ABCL